Form 4: aTyr Pharma Director Eric Benevich Acquires 50,000 Stock Options
SEC Form 4 Filing
Director Eric Benevich acquired 50,000 stock options in aTyr Pharma, according to a recent SEC Form 4 filing.
Summary
- Eric Benevich, a director at aTyr Pharma, acquired 50,000 stock options on May 1, 2025.
- The exercise price of these options is $3.34.
- The options vest fully on the earlier of May 1, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
- The options expire on May 1, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is a standard compensation practice.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC filing related to insider transactions. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of transaction: Eric Benevich acquired 50,000 stock options at an exercise price of $3.34. |
| 05/01/2026 | Earliest vesting date for the stock options, contingent on continued service on the Board of Directors. |
| 05/01/2035 | Expiration date of the stock options. |
Keywords
aTyr Pharma, Eric Benevich, stock options, director, SEC Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.